Dr. San Miguel on Pembrolizumab With Lenalidomide/Dexamethasone in Multiple Myeloma

Dr. San Miguel on Pembrolizumab With Lenalidomide/Dexamethasone in Multiple Myeloma

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.